Another investor attack launched against a pharma patent at the PTAB; and Kyle Bass is not involved

An IPR has been filed against an Allergan patent by an investment firm in a move that will heighten fears in the life sciences industries about the potential damage the PTAB process could do to their IP rights. The latest move comes after two…

Get unlimited access to all IAM content